Idexx Laboratories Stock Performance
| IDXX Stock | USD 514.61 4.10 0.79% |
On a scale of 0 to 100, IDEXX Laboratories holds a performance score of 18. The company retains a Market Volatility (i.e., Beta) of 0.92, which attests to possible diversification benefits within a given portfolio. IDEXX Laboratories returns are very sensitive to returns on the market. As the market goes up or down, IDEXX Laboratories is expected to follow. Please check IDEXX Laboratories' downside variance, and the relationship between the total risk alpha and daily balance of power , to make a quick decision on whether IDEXX Laboratories' current trending patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in IDEXX Laboratories are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, IDEXX Laboratories showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.79) | Five Day Return (3.03) | Year To Date Return 25.87 | Ten Year Return 711.69 | All Time Return 108.8 K |
Last Split Factor 2:1 | Last Split Date 2015-06-16 |
1 | Acquisition by Britt Irene Chang of 257 shares of IDEXX Laboratories subject to Rule 16b-3 | 05/07/2025 |
2 | Snowden Capital Advisors LLC Cuts Stock Holdings in IDEXX Laboratories, Inc. | 05/22/2025 |
3 | Three Lawmakers Bought This Biotech Stock Before Supporting A Bill That Could Boost Its Value Its Now Up 44 | 06/11/2025 |
4 | Sabal Trust CO Increases Stock Holdings in IDEXX Laboratories, Inc. | 06/26/2025 |
5 | Reviewing IDEXX Laboratories and Biosig Technologies | 07/07/2025 |
6 | Heres How Much Youd Have If You Invested 1000 in Idexx Laboratories a Decade Ago | 07/08/2025 |
7 | Want Better Returns Dont Ignore These 2 Medical Stocks Set to Beat Earnings | 07/09/2025 |
8 | IDEXX Laboratories Announces Election of New Independent Director | 07/10/2025 |
9 | Allworth Financial LP Grows Stock Position in IDEXX Laboratories, Inc. | 07/14/2025 |
10 | IDEXX Laboratories, Inc. Shares Purchased by Apollon Wealth Management LLC | 07/16/2025 |
11 | Dynasty Wealth Management LLC Makes New 234,000 Investment in IDEXX Laboratories, Inc. | 07/18/2025 |
| Begin Period Cash Flow | 453.9 M | |
| Total Cashflows From Investing Activities | -207.1 M |
IDEXX Laboratories Relative Risk vs. Return Landscape
If you would invest 40,665 in IDEXX Laboratories on April 20, 2025 and sell it today you would earn a total of 10,796 from holding IDEXX Laboratories or generate 26.55% return on investment over 90 days. IDEXX Laboratories is currently generating 0.3938% in daily expected returns and assumes 1.6696% risk (volatility on return distribution) over the 90 days horizon. In different words, 14% of stocks are less volatile than IDEXX, and 93% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IDEXX Laboratories Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IDEXX Laboratories' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as IDEXX Laboratories, and traders can use it to determine the average amount a IDEXX Laboratories' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2359
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IDXX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.67 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.39 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.24 actual daily | 18 82% of assets perform better |
Based on monthly moving average IDEXX Laboratories is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IDEXX Laboratories by adding it to a well-diversified portfolio.
IDEXX Laboratories Fundamentals Growth
IDEXX Stock prices reflect investors' perceptions of the future prospects and financial health of IDEXX Laboratories, and IDEXX Laboratories fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IDEXX Stock performance.
| Return On Equity | 0.59 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.32 % | ||||
| Current Valuation | 43.25 B | ||||
| Shares Outstanding | 80.42 M | ||||
| Price To Earning | 61.31 X | ||||
| Price To Book | 29.51 X | ||||
| Price To Sales | 10.53 X | ||||
| Revenue | 3.9 B | ||||
| Gross Profit | 2.41 B | ||||
| EBITDA | 1.28 B | ||||
| Net Income | 887.87 M | ||||
| Cash And Equivalents | 114.36 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 265.62 M | ||||
| Debt To Equity | 3.27 % | ||||
| Current Ratio | 0.89 X | ||||
| Book Value Per Share | 17.93 X | ||||
| Cash Flow From Operations | 929 M | ||||
| Earnings Per Share | 10.81 X | ||||
| Market Capitalization | 41.39 B | ||||
| Total Asset | 3.29 B | ||||
| Retained Earnings | 5.33 B | ||||
| Working Capital | 331.98 M | ||||
| Current Asset | 821.63 M | ||||
| Current Liabilities | 856.76 M | ||||
About IDEXX Laboratories Performance
Evaluating IDEXX Laboratories' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if IDEXX Laboratories has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IDEXX Laboratories has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 91.79 | 119.88 | |
| Return On Tangible Assets | 0.32 | 0.34 | |
| Return On Capital Employed | 0.51 | 0.26 | |
| Return On Assets | 0.27 | 0.28 | |
| Return On Equity | 0.56 | 0.58 |
Things to note about IDEXX Laboratories performance evaluation
Checking the ongoing alerts about IDEXX Laboratories for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for IDEXX Laboratories help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| IDEXX Laboratories currently holds 265.62 M in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about IDEXX Laboratories' use of debt, we should always consider it together with its cash and equity. | |
| Over 98.0% of IDEXX Laboratories shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Dynasty Wealth Management LLC Makes New 234,000 Investment in IDEXX Laboratories, Inc. |
- Analyzing IDEXX Laboratories' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether IDEXX Laboratories' stock is overvalued or undervalued compared to its peers.
- Examining IDEXX Laboratories' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating IDEXX Laboratories' management team can have a significant impact on its success or failure. Reviewing the track record and experience of IDEXX Laboratories' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of IDEXX Laboratories' stock. These opinions can provide insight into IDEXX Laboratories' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.